Form 4: 10x Genomics CEO Exercises Options, Increases Stake

10x Genomics CEO Serge Saxonov exercised stock options to acquire 50,000 shares of Class A Common Stock at $1.20 per share, increasing his direct beneficial ownership.

Summary

• Serge Saxonov, CEO and Director of 10x Genomics, Inc. (TXG), acquired 50,000 shares of Class A Common Stock.
• The acquisition occurred on January 5, 2026, through the exercise of stock options.
• The exercise price for these shares was $1.20 per share.
• Following this transaction, Saxonov directly beneficially owns 1,071,556 shares of Class A Common Stock.
• He also indirectly beneficially owns 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants' Trust, and 58,000 shares through the Y/S Pot Trust, for which he serves as trustee.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• All exercised options were fully vested and exercisable as of the transaction date.
• After the transaction, Saxonov retains 173,600 unexercised stock options.

Sentiment

Score: 7

Explanation: The exercise of stock options by the CEO to acquire a significant number of shares, especially at a low exercise price, generally indicates management's confidence in the company's future prospects. This is a positive signal for investors.

Positives

• CEO Serge Saxonov increased his direct beneficial ownership by 50,000 shares, signaling confidence in the company's future.
• The transaction was executed at a low exercise price of $1.20, indicating potential value from previously granted options.
• The transaction was conducted under a Rule 10b5-1(c) plan, suggesting a pre-planned, non-discretionary acquisition.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Corporate Governance

Related Party Transactions

• Serge Saxonov serves as trustee for the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust, which indirectly hold shares of 10x Genomics Class A Common Stock. These are disclosed as indirect beneficial ownership.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, signaling management's belief in the company's value.

Key Dates

Keywords

10x Genomics, TXG, Serge Saxonov, Form 4, insider transaction, stock options, CEO, beneficial ownership, Rule 10b5-1, equity acquisition